A recent study1 commissioned by Noble International analyzed the biologic initiation process and current gaps pertaining to patient guidance and self-injection training practices. Anecdotal evidence showed that more than one-third of participating patients lacked the necessary confidence to self-inject during their first six months of treatment due to inadequate training practices. The study further maintained […]

Unmet Training Needs For Patients Using Self-Injectable Drug Therapies Comes At A High Cost A recent report published in Expert Opinion On Drug Delivery uncovered a startling paradigm regarding unmet training needs for patients who begin self-injectable therapies for chronic disease management. The authors of the report, “The current paradigm for biologic initiation: a mixed-methods […]

In today’s evolving healthcare environment, it’s not surprising that biosimilars have become more widely prescribed by physicians as an affordable alternative to biologics, which have been estimated to account for 38-40% of all pharmaceutical spending and average more than $100,000 per patient per year.1 Following this trend, in 2021, the biosimilar global market size was […]

Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing & Patient Services The global market for medical devices is approximately $436 billion, bolstered by an aging population, according to data from hfMEDIC, the University of Utah-led […]

Noble Can Help Alleviate Patient Anxieties Caused by Switching to Biosimilar Therapies Change can be difficult for patients, particularly when embarking on a new treatment plan. Patients who require treatments for a variety of chronic illnesses—ranging from diabetes and rheumatoid arthritis to multiple sclerosis, Crohn’s disease and cancer— are increasingly prescribed biosimilar therapies to self-inject […]